Effect of Hydroxychloroquine in patients with repeated implantation failure

Immunomodulatory Effects of Hydroxychloroquine on immunological factors involved in implantation of women with repeated implantation failure: clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017060634209N1

Enrollment

Registered

2017-07-13

Start date

2017-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Repeated Implantation Failure. Female infertility of uterine origin

Interventions

Women receive oral Hydroxychloroquine (400 mg/day) for 16 days.

Treatment - Drugs

Women receive oral Hydroxychloroquine (400 mg/day) for 16 days

Eligibility

Sex/Gender

Female

Age

25 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients having an immunological disorder in serum (Tumor necrosis factor alpha/Interleukin-10>= 30.6); 3 failed embryo transfer Exclusion criteria: uterine abnormality (acquired or congenital); unwillingness to continue

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Interleukin -10. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;Tumor necrosis factor alfa. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;Interleukin-17. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;GATA3 gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.;Interleukin-4. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;T-bet gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.;FOXP-3 gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.;ROR?t gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.	—

Measure

Time frame

Interleukin -10. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;Tumor necrosis factor alfa. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;Interleukin-17. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;GATA3 gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.;Interleukin-4. Timepoint: Twice: before and after intervention. Method of measurement: Immunohistochemistry.;T-bet gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.;FOXP-3 gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.;ROR?t gene. Timepoint: Twice: before and after intervention. Method of measurement: Polymerase chain reaction.

—

Secondary

Measure	Time frame
Chemical pregnancy. Timepoint: 2 weeks after embryo transfer in next cycle. Method of measurement: Serum BHCG.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Sonia Sadeghpour

Urmia University of Medical Sciences

dr.sadeghpour.s@gmail.com+98 44 3319 7713

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026